Research programme: antiviral monoclonal antibodies - Savoy Pharmaceuticals
Alternative Names: ViroprevLatest Information Update: 28 Sep 2025
At a glance
- Originator Savoy Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Viral-infections in USA (Parenteral)
- 22 Sep 2023 Antiviral monoclonal antibodies are still in preclinical development for Viral infections in USA (Savoy Pharmaceuticals pipeline, September 2023)
- 30 Jan 2019 Research programme: antiviral monoclonal antibodies is still in preclinical phase for Viral infections in USA (Savoy Pharmaceuticals pipeline, January 2019)